Form PT0-1595 III-17-1 Form PT0-1595 III-17-1 (Rev. 03/01) III-17-1 OMB No. 0651-0027 (exp. 5/31/2002) 1026016 Tab settings ⇒ ⇒ ▼ III-17-1	U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office
	Please record the attached original documents or copy thereof.
1. Name of conveying party(ies): Abbott Laboratories, S.A.	2. Name and address of receiving party(ies) Name:
Additional name(s) of conveying party(les) attached? 🎴 Yes 🎽 No	
3. Nature of conveyance:	
Assignment Greement Change of Name	Street Address: <u>300 Technology Square</u>
Other	Cambridge MA 02139 City:State:Zip:
Execution Date: <u>July 3, 2003</u>	Additional name(s) & address(es) attached? 🎴 Yes 🧧 No
Additional numbers at 5. Name and address of party to whom correspondence concerning document should be mailed: France Côté Name:	ached? Yes No 6. Total number of applications and patents involved: 7. Total fee (37 CFR 3.41)
Internal Address: Ogilvy Renault	Enclosed Authorized to be charged to deposit account
1600 - 1981 McGill College Avenue Street Address:	8. Deposit account number: 19-5113
MontréalQuébec H3A 2Y3 City:State:Zip:	(Attach duplicate copy of this page if paying by deposit account)
	THIS SPACE
Mail documents to be recorded with Commissioner of Patents & T	r sheet, attached sorrect and any attached copy Jolo7/c3 Date Trequired cover sheet information to: Trademarks, Box Assignments D.C. 20231

.

Exhibit B

Patent Assignment

THIS PATENT ASSIGNMENT is made as of July 32, 2003, by Abbott Laboratories, S.A., a Spanish company having offices at calle Josefa Valcárel, 48, 28027 Madrid, Spain ("<u>Assignor</u>") and Xanthus Life Sciences, a Delaware corporation with offices at 300 Technology Square, Cambridge, MA 02139 ("<u>Assignee</u>").

WITNESSETH

WHEREAS, Assignor is the owner of the entire and exclusive right, title and interest worldwide in, to and under means U.S. Patent No. 5,183,821 and any respective inventions disclosed, claimed or represented therein, and any renewals, revivals, substitutes, divisions, reissues, reexaminations, continuations, continuations-in-part and extensions thereof, and all patents that may issue on any of the foregoing, together with all rights in and to any and all causes of action heretofore or hereafter accrued or accruing for infringement or threatened or alleged infringement of such patent rights (the "Assigned Rights"); and

WHEREAS, Assignor's ownership of all rights, title and interest in, to and under the Assigned Rights is pursuant to the transfer of the same from Assignor's predecessor at interest, Laboratorios Knoll, S.A., to Assignor as attested to in the Certification attached hereto; and

WHEREAS, Assignee is desirous of acquiring the entire and exclusive right, title and interest in, to and under the Assigned Rights, and Assignor is desirous of assigning the Assigned Rights to Assignee;

NOW, THEREFORE,

Assignor, for good and valuable consideration including without limitation consideration given to Abbott GmbH & Co. KG pursuant to that certain agreement entered into between Abbott GmbH & Co. KG and Assignee on or about the date hereof, the receipt and sufficiency of which is hereby acknowledged by Assignor, hereby sells, assigns, and transfers to Assignee, its successors and assigns, the entire and exclusive right, title and interest worldwide in, to and under the Assigned Rights, to be held and enjoyed by Assignee for its own use and enjoyment including the right to prepare, file, prosecute, maintain, defend and enforce the Assigned Rights, and for the use and enjoyment of its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment had not been made, together with all claims for damages by reason of past infringement of the Assigned Rights, with the right to sue for and collect on such claims for its own use and enjoyment, and for the use and enjoyment of its successors and assigns.

Assignor hereby represents and warrants that it is the sole and exclusive lawful owner of, and has good and marketable title to, all right, title, and interest in and to the Assigned Rights free and clear of all liens, claims or other encumbrances, and it has the legal right and power to assign and transfer the entire interest in and to the Assigned Rights to Assignee. Assignor

PATENT REEL: 014692 FRAME: 0532 further represents and agrees that it shall execute all documents reasonably necessary to effectuate this Patent Assignment and to take all actions reasonably necessary to perfect title to the Assigned Rights with Assignee.

Assignor, as owner of the entire right, title and interest in the Assigned Rights, hereby authorizes and requests the United States Patent and Trademark Office, or other proper governmental authority, to issue to Assignee, its successors and assigns, all patents or other patent rights included within the Assigned Rights or issuing therefrom.

IN WITNESS WHEREOF, Assignor has caused this Patent Assignment to be signed by its duly authorized officer effective as of the date first written above.

Abbott Laborator ANTONIO GARCIO Name: Title: <u>FinAnce</u> PIRETOR 1064, 3.2003 Name of Witness: JUNU C. LIRINS Address of Witness: VICENTE ALEIXANDRE, 6 28922 MADRID

PATENT REEL: 014692 FRAME: 0533



Patent Attorney's Docket No. <u>12926-30US</u> FC/TM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Miguel F. Brana et al.

SERIAL NO.: 728,025

PATENT NO.: 5,183,821

FILED: July 8, 1991

FOR: METHOD FOR TREATING LEUKEMIAS USING N-(2-DIMETHYLAMINOETHYL)-3-AMINO-1,8-NAPHTHALIMIDE FOR TREATING LEUKEMIAS AND SOLID TUMORS

RECORDATION OF ASSIGNMENT

Assistant Commissioner for Patents Washington, DC 20231

Sir:

There is submitted herewith an Assignment from the Assignee in favor of XANTHUS LIFE SCIENCES with respect to the above-noted United States patent, together with a Recordation Form Cover Sheet PTO-1595, in duplicate.

It is respectfully requested that the Assignment be registered against this United States patent.

----- F -----

Authorization is hereby given to charge Deposit Account No. 19-5113 the amount of \$40.00 to cover the costs for this registration or to cover any underpayment or to credit any overpayment.

10-08-2003 U.S. Patent & TMOfc/TM Mail Rcpt Dt. #74

PATENT REEL: 014692 FRAME: 0534 Patent No.: 5,183,821

Respectfully submitted,

Date: 10/07/03

By:

Christian Cawthorn, Reg. No. 47,352 Agent of records

OGILVY RENAULT 1981 McGill College, Suite 1600 Montréal (Québec) Canada, H3A 2Y3

Tel: (514) 847-4256

Encl: Assignment in favor of Xanthus Life Sciences Form PTO-1595, in duplicate

RECORDED: 10/08/2003